These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 24608297)

  • 1. Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.
    Fraunholz IB; Haberl A; Klauke S; Gute P; Rödel CM
    Dis Colon Rectum; 2014 Apr; 57(4):423-31. PubMed ID: 24608297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy.
    Fraunholz I; Weiss C; Eberlein K; Haberl A; Rödel C
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1425-32. PubMed ID: 19744801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy.
    Blazy A; Hennequin C; Gornet JM; Furco A; Gérard L; Lémann M; Maylin C
    Dis Colon Rectum; 2005 Jun; 48(6):1176-81. PubMed ID: 15906137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
    Seo Y; Kinsella MT; Reynolds HL; Chipman G; Remick SC; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):143-9. PubMed ID: 19203845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy.
    Wexler A; Berson AM; Goldstone SE; Waltzman R; Penzer J; Maisonet OG; McDermott B; Rescigno J
    Dis Colon Rectum; 2008 Jan; 51(1):73-81. PubMed ID: 18066626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer.
    Hauerstock D; Ennis RD; Grossbard M; Evans A
    Clin Colorectal Cancer; 2010 Oct; 9(4):238-42. PubMed ID: 20920996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV Infection Is Associated With Poor Outcomes for Patients With Anal Cancer in the Highly Active Antiretroviral Therapy Era.
    Grew D; Bitterman D; Leichman CG; Leichman L; Sanfilippo N; Moore HG; Du K
    Dis Colon Rectum; 2015 Dec; 58(12):1130-6. PubMed ID: 26544809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage surgery for residual primary and locally recurrent anal squamous cell carcinoma after chemoradiotherapy in HIV-positive individuals.
    Cunin L; Alfa-Wali M; Turner J; Bower M; Ion L; Allen-Mersh T
    Ann Surg Oncol; 2014 Feb; 21(2):527-32. PubMed ID: 24242676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.
    Eng C; Chang GJ; You YN; Das P; Xing Y; Delclos M; Wolff RA; Rodriguez-Bigas MA; Skibber J; Ohinata A; Gould S; Phillips J; Crane CH
    Cancer; 2013 Nov; 119(21):3769-75. PubMed ID: 24037775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic significance of pretreatment leukocytosis in patients with anal cancer treated with radical chemoradiotherapy or radiotherapy.
    Banerjee R; Roxin G; Eliasziw M; Joseph K; Maclean A; Buie WD; Doll C
    Dis Colon Rectum; 2013 Sep; 56(9):1036-42. PubMed ID: 23929012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of anal cancer patients at the Ottawa hospital.
    Abunassar M; Reinders J; Jonker DJ; Asmis T
    Eur J Surg Oncol; 2015 May; 41(5):653-8. PubMed ID: 25776438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Toxicity and Treatment Outcomes in HIV-positive Versus HIV-negative Patients With Squamous Cell Carcinoma of the Anal Canal.
    White EC; Khodayari B; Erickson KT; Lien WW; Hwang-Graziano J; Rao AR
    Am J Clin Oncol; 2017 Aug; 40(4):386-392. PubMed ID: 25513996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy.
    Doyen J; Benezery K; Follana P; Ortholan C; Gérard JP; Hannoun-Levi JM; Gal J; Francois E
    Dis Colon Rectum; 2013 Oct; 56(10):1125-33. PubMed ID: 24022529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities.
    Edelman S; Johnstone PA
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):206-11. PubMed ID: 16904522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
    Chen YW; Yen SH; Chen SY; Huang PI; Shiau CY; Liu YM; Lin JK; Wang LW
    J Surg Oncol; 2007 Oct; 96(5):374-80. PubMed ID: 17492635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
    Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy.
    Rödel F; Wieland U; Fraunholz I; Kitz J; Rave-Fränk M; Wolff HA; Weiss C; Wirtz R; Balermpas P; Fokas E; Rödel C
    Int J Cancer; 2015 Jan; 136(2):278-88. PubMed ID: 24839133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy?
    Fraunholz I; Rabeneck D; Gerstein J; Jäck K; Haberl A; Weiss C; Rödel C
    Radiother Oncol; 2011 Jan; 98(1):99-104. PubMed ID: 21168927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
    James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
    Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy.
    Oehler-Jänne C; Huguet F; Provencher S; Seifert B; Negretti L; Riener MO; Bonet M; Allal AS; Ciernik IF
    J Clin Oncol; 2008 May; 26(15):2550-7. PubMed ID: 18427149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.